AOD-9604 research guide

AOD-9604 in Disod — Fat Loss Peptide Research Guide

AOD-9604 research guide for Disod. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.

Skip to Sourcing Guide Order AOD-9604 →

AOD-9604 in Disod: Sourcing, Purity & Protocols

AOD-9604 isn't available on pharmacy shelves in Disod or virtually any local market — it's a research compound supplied via a dedicated online market. This concentration of supply in online vendors is actually an advantage for quality — top vendors compete on lab-verified purity in ways no local retailer can match. Vendors worth sourcing from make readily available batch-matched Certificates of Analysis showing HPLC chromatograms, mass spec identity confirmation, endotoxin levels, and residual solvent results — all for the precise product run you are purchasing. What follows is a practical research guide built specifically around AOD-9604, covering everything a Disod researcher needs before placing a first order.

The Science Behind AOD-9604

CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: AOD-9604 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Disod comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.

Sourcing Research-Grade AOD-9604

Assessing AOD-9604 vendors begins with the COA: request the batch-specific certificate before placing an order, not after. The HPLC analytical chromatogram is the most important document in the COA: it should show a clear dominant peak representing AOD-9604, with small or absent impurity peaks representing impurities — purity should be stated as ≥98%. Strong quality indicators beyond COA quality: multi-year operating history, responsive technical support who understand testing methodology, and shipping with desiccant and appropriate cold protection. Bacteriostatic water is the standard reconstitution medium for AOD-9604 — it contains 0.9% benzyl alcohol that prevents microbial contamination and extends reconstituted shelf life to 4 weeks when kept refrigerated.

Order AOD-9604 — ships to Disod
COA-verified · International tracking · Research grade
Order Now →

AOD-9604: Storage, Reconstitution & Safety

AOD-9604 is supplied strictly for research applications and is not approved for human use by the FDA or comparable health authorities — all information here is educational. Temperature excursions — even temporary temperature deviation — can cause partial degradation without any obvious sign; always verify cold chain was maintained during shipping. Endotoxin testing in the AOD-9604 COA is absolutely required — gram-negative bacterial endotoxins can trigger serious inflammatory reactions at very low concentrations, and no pricing advantage justifies skipping this verification. For any individual considering AOD-9604 outside a formal research context: seek medical advice first — this compound is unapproved for human therapeutic application and its safety characterisation does not match that of regulated drugs.

Frequently Asked Questions

What is AOD-9604?

AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.

What is the clinical trial history of AOD-9604?

AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.

How does AOD-9604 differ from growth hormone?

AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.

Order AOD-9604 today
COA-verified · International shipping available
Order Now →